logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Q4 2018
EYEGATE PHARMACEUTICALS INC
Top-line data from ongoing Ocular Bandage Gel (OBG) study
Corneal staining with Punctate epitheliopathies (PE) due to pathologies
Q4 2018
EYEGATE PHARMACEUTICALS INC
Top-line data from ongoing Ocular Bandage Gel (OBG) study
Corneal defects due to photorefractive keratectomy (PRK) surgery
Oct 2018
Menlo Therapeutics, Inc.
Data from phase II trial of Serlopitant
Refractory Chronic Cough
Q4 2018
Biohaven Pharmaceutical Holding Co Ltd.
Preliminary readout of long-term safety study of Rimegepan
Acute treatment of migraine
Q4 2018
Biohaven Pharmaceutical Holding Co Ltd.
Topline results from Phase 3 Rimegepant Zydis ODT trial
Acute treatment of migraine
Q4 2018
Unum Therapeutics Inc.
Initial data from phase I trial of ACTR087 in combination with SEA-BCMA (ATTCK-17-01)
Relapsed or refractory Multiple Myeloma
Q4 2018
Unum Therapeutics Inc.
Preliminary Data from Phase I Trial of ACTR707 in Combination with Rituximab (ATTCK-20-03)
CD20+ relapsed or refractory non-Hodgkin lymphoma
Q4 2018
Endo International plc
Top-line results from two phase III trials for collagenase clostridium histolyticum
Cellulite
Q4 2018
Puma Biotechnology Inc.
Additional data from phase II study of Neratinib (CONTROL)
Extended adjuvant treatment of HER2-positive early stage breast cancer
Q4 2018
Puma Biotechnology Inc.
Additional data from Phase II trial of Neratinib (SUMMIT)
Solid tumors with activating EGFR, HER2 or HER4 mutations
Q4 2018
Cocrystal Pharma, Inc.
Top line results from Phase 2a study of CC-31244
Hepatitis C virus
Q4 2018
Aevi Genomic Medicine Inc.
Top-line data from part A phase II study of AEVI-001 (ASCEND)
Attention Deficit Hyperactivity Disorder (ADHD)
Q4 2018
Aevi Genomic Medicine Inc.
Top-line data from part B phase II study of AEVI-001 (ASCEND)
Attention Deficit Hyperactivity Disorder (ADHD)
Q4 2018
Mesoblast Limited
Filing of BLA for MSC-100-IV
Steroid refractory acute Graft Versus Host Disease
Q4 2018
Axsome Therapeutics, Inc.
Results from final interim analysis of phase III trial of AXS-05 (STRIDE-1)
Treatment resistant depression(TRD)
Q4 2018
Axsome Therapeutics, Inc.
Results from first interim analysis of Phase 2/3 trial of AXS-05 (ADVANCE-1)
Agitation associated with Alzheimer's disease
Q4 2018
Axsome Therapeutics, Inc.
Top line results from phase II trial of AXS-05 (ASCEND)
Major depressive disorder
Q4 2018
SAGE Therapeutics, Inc.
Top-line data from placebo-controlled pivotal trial of SAGE-217
Postpartum Depression
Q4 2018
Tesaro Inc.
Submission of sNDA seeking label expansion for ZEJULA
Maintenance treatment of patients with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
Q4 2018
Aileron Therapeutics, Inc.
Additional interim data from Phase 2a trial of ALRN-6924
Peripheral T-cell lymphoma
Q4 2018
Aileron Therapeutics, Inc.
Interim data from Phase 1 and 1b open-label, multi-center clinical trials of ALRN-6924
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
Q4 2018
Foamix Pharmaceuticals Ltd.
Top-line result from Phase 3 clinical study of FMX103 (FX2016-11)
Moderate-to-severe papulopustular rosacea
Q4 2018
Foamix Pharmaceuticals Ltd.
Top-line result from Phase 3 clinical study of FMX103 (FX2016-12)
Moderate-to-severe papulopustular rosacea
Q4 2018
Endocyte, Inc.
Submission of IND for EC17/CAR T-cell therapy
Osteosarcoma
Q4 2018
Arbutus Biopharma Corp.
Interim 6-week results from ongoing phase II study of ARB-1467 in combination with tenofovir (TDF), and pegylated interferon
Chronic Hepatitis B Virus (HBV)